Last updated: February 15, 2026
Overview
The drug identified by NDC 68462-0684 is Dexamethasone, a corticosteroid used for inflammation, autoimmune conditions, and certain cancers. Its manufacturing and market dynamics are influenced by generic availability, patents, and approval status. Since Dexamethasone has been on the market for decades, current market activity largely involves generic versions, which exert downward pressure on prices.
Market Dynamics
- Generic Competition: Multiple manufacturers produce Dexamethasone, with price competition resulting in low-cost options.
- Demand Drivers: Uses include autoimmune disorders, allergic reactions, and as a part of COVID-19 treatment protocols (notably in early 2020). Demand fluctuates with disease prevalence and treatment guidelines.
- Supply Chain: Suppliers include major generic drug companies, compounded medication producers, and hospital formulary suppliers.
- Regulatory Status: The drug is off-patent; no new patent applications hinder generic entry. The absence of exclusivity supports market saturation and price stability at low levels.
Pricing Data and Trends
- Current Average Wholesale Price (AWP): Approximately $0.05 to $0.10 per 4 mg tablet (based on 2023 data).
- Recent Trends: Slight price decreases observed over the last five years; driven by increased generic supply and manufacturing efficiencies.
- Reimbursement Rates: Medicaid and private insurers reimburse at or below AWP, limiting potential revenue increases for manufacturers.
| Year |
Average Price per 4 mg Tablet |
Notes |
| 2018 |
$0.07 |
Pre-pandemic baseline. |
| 2020 |
$0.06 |
Pandemic-related demand spikes, stabilization. |
| 2022 |
$0.05 |
Market saturation with generics. |
| 2023 |
$0.05 – $0.10 |
Variability across suppliers and regions. |
Price Projection Outlook
- Short-term (1-2 years): Prices are expected to stabilize or decline slightly, remaining within the range of $0.05 – $0.10 per tablet.
- Medium-term (3-5 years): Advances in formulation or new delivery methods are unlikely due to off-patent status. Market saturation and ongoing generics competition suggest minimal upward movement.
- Long-term (>5 years): No significant changes forecast; prices likely to stay within current margins unless manufacturing costs drastically change or new formulations receive approval.
Market Opportunities and Challenges
- Opportunities: Growing use in certain countries with expanding healthcare infrastructure may offer niche markets.
- Challenges: Price erosion driven by GDUFA (Generic Drug User Fee Amendments) and increased generic manufacturing capacity limit revenue potential.
Conclusion
The NDC 68462-0684 corresponds to a generic Dexamethasone product with a mature market characterized by low prices and high competition. Price trends will remain low, with slight fluctuations attributable to supply chain factors. No significant price increases are likely absent formulation innovations or new indication approvals.
Key Takeaways
- The drug is a widely generic corticosteroid with a mature market and low price points.
- Current wholesale prices hover around $0.05–$0.10 per tablet.
- Market saturation limits upside; prices are expected to stay stable or decline gradually.
- Demand fluctuations coincide with treatment guidelines, especially in contexts like COVID-19.
- Long-term prospects depend on formulation or indication innovations rather than market expansion or patent protections.
FAQs
Q1: How does patent status affect the price of NDC 68462-0684?
A1: The drug is off-patent, enabling multiple manufacturers to produce it, which sustains price competition and keeps prices low.
Q2: Are there formulary barriers affecting Dexamethasone prices?
A2: Dexamethasone is widely accepted in hospital and outpatient settings with minimal formulary restrictions, especially due to its low cost and BOP (basic off-patent) status.
Q3: Could new formulations increase the price?
A3: Unlikely in the near term, as current formulations are established and no new patent protections are pursued.
Q4: How has COVID-19 affected the market?
A4: Initial increased demand in 2020 caused short-term price spikes; however, prices normalized as supply stabilized.
Q5: What is the outlook for future generic competition?
A5: Continued generics production and manufacturing efficiencies will keep prices stable or declining over the next several years.
Citations
- IBM Watson Micromedex, 2023.
- Red Book Online, 2023.
- FDA Orange Book, 2023.
- GoodRx, 2023.
- Medicare formularies, 2023.
[1] https://www.fda.gov/drugs/drug-approvals-and-databases-orange-book
